色素性视网膜炎
物候学
背景(考古学)
生物
视网膜变性
RPE65型
遗传学
遗传增强
人性化鼠标
基因
转导(生物物理学)
突变
清脆的
遗传异质性
体内
分子生物学
表型
古生物学
生物化学
作者
Wen-Hsuan Wu,Yi-Ting Tsai,I-Wen Huang,Chia-Hua Cheng,Chun-Wei Hsu,Xuan Cui,Joseph Ryu,Peter M Quinn,Salvatore Marco Caruso,Chyuan-Sheng Lin,Stephen H. Tsang
标识
DOI:10.1016/j.ymthe.2022.02.010
摘要
Mutations in rhodopsin (RHO) are the most common causes of autosomal dominant retinitis pigmentosa (adRP), accounting for 20% to 30% of all cases worldwide. However, the high degree of genetic heterogeneity makes development of effective therapies cumbersome. To provide a universal solution to RHO-related adRP, we devised a CRISPR-based, mutation-independent gene ablation and replacement (AR) compound therapy carried by a dual AAV2/8 system. Moreover, we developed a novel hRHOC110R/hRHOWT humanized mouse model to assess the AR treatment in vivo. Results show that this humanized RHO mouse model exhibits progressive rod-cone degeneration that phenocopies hRHOC110R/hRHOWT patients. In vivo transduction of AR AAV8 dual vectors remarkably ablates endogenous RHO expression and overexpresses exogenous WT hRHO. Furthermore, the administration of AR during adulthood significantly hampers photoreceptor degeneration both histologically and functionally for at least 6 months compared with sole gene replacement or surgical trauma control. This study demonstrates the effectiveness of AR treatment of adRP in the human genomic context while revealing the feasibility of its application for other autosomal dominant disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI